Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH
The available treatment options for hyponatremia secondary to SIADH are limited and not completely effective. Conivaptan is a vasopressin 1a and 2 receptor antagonist recently approved by the US Food and Drug Administration (FDA) for treating euvolemic and hypervolemic hyponatremia in adult patients...
Gespeichert in:
| Veröffentlicht in: | Pediatric nephrology (Berlin, West) West), 2008-08, Vol.23 (8), p.1367-1370 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1370 |
|---|---|
| container_issue | 8 |
| container_start_page | 1367 |
| container_title | Pediatric nephrology (Berlin, West) |
| container_volume | 23 |
| creator | Rianthavorn, Pornpimol Cain, Joan P. Turman, Martin A. |
| description | The available treatment options for hyponatremia secondary to SIADH are limited and not completely effective. Conivaptan is a vasopressin 1a and 2 receptor antagonist recently approved by the US Food and Drug Administration (FDA) for treating euvolemic and hypervolemic hyponatremia in adult patients. However, data on efficacy and safety of conivaptan in pediatrics are limited. We report a case of a 13-year-old boy with extensively metastasized anaplastic large-cell lymphoma. He also developed hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) prior to chemotherapy initiation. SIADH management in this case was complicated when fluid restriction was not safely attainable. Conivaptan played a significant role in this situation by allowing provision of a large amount of intravenous fluid prior to and during induction chemotherapy. It proved to be an important component in preventing uric acid nephropathy/tumor lysis syndrome. Conivaptan induced free-water clearance as indicated by increased urine output and decreased urine osmolality. The patient responded to conivaptan without any adverse effects. |
| doi_str_mv | 10.1007/s00467-008-0809-y |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_20027911</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A385406847</galeid><sourcerecordid>A385406847</sourcerecordid><originalsourceid>FETCH-LOGICAL-c533t-8602aa63a66b4579cd6b216801286ad3df93d695c64ae718aa70e2a2ca1c3c623</originalsourceid><addsrcrecordid>eNp1kstu1DAUhiMEokPhAdggi0V3Kb4kjrMcFXqRKrGASt1FZ5yTjCvHDnYyVR6Bt8bDjFRARV5Y8vk-6_j4z7L3jJ4zSqtPkdJCVjmlKqeK1vnyIluxQvCc1er-ZbaitWA5Ldj9SfYmxgeawFLJ19kJU4WoCq5W2c-7iMR3RHtndjBO4MjkCVjrHwn0fcAYzQ7JdmkDTMb_ro4Bd-gmMs2DD8Qu0UQSF9cGPyAxjgAZsTUwBaPJmKw9-2imLbEQesw1WpusYdz6AQi4lny7WX--fpu96sBGfHfcT7O7yy_fL67z269XNxfr21yXQky5kpQDSAFSboqyqnUrN5xJRRlXElrRdrVoZV1qWQBWTAFUFDlwDUwLLbk4zc4O947B_5gxTs1g4r4ncOjn2HBKeVUzlsCP_4APfg4u9dZwzkXJ0iwTlB-gHiw2xnV-CqB7dBjAeoedScdrocqCSlVUiT9_hk-rxcHoZ4WzP4Qtgp220dt5_xnxb5AdQB18jAG7ZgxmgLA0jDb7uDSHuDQpBc0-Ls2SnA_HJ86bAdsn45iPBPADEFPJ9RieZvD_W38BSJ_LNA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222351586</pqid></control><display><type>article</type><title>Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Rianthavorn, Pornpimol ; Cain, Joan P. ; Turman, Martin A.</creator><creatorcontrib>Rianthavorn, Pornpimol ; Cain, Joan P. ; Turman, Martin A.</creatorcontrib><description>The available treatment options for hyponatremia secondary to SIADH are limited and not completely effective. Conivaptan is a vasopressin 1a and 2 receptor antagonist recently approved by the US Food and Drug Administration (FDA) for treating euvolemic and hypervolemic hyponatremia in adult patients. However, data on efficacy and safety of conivaptan in pediatrics are limited. We report a case of a 13-year-old boy with extensively metastasized anaplastic large-cell lymphoma. He also developed hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) prior to chemotherapy initiation. SIADH management in this case was complicated when fluid restriction was not safely attainable. Conivaptan played a significant role in this situation by allowing provision of a large amount of intravenous fluid prior to and during induction chemotherapy. It proved to be an important component in preventing uric acid nephropathy/tumor lysis syndrome. Conivaptan induced free-water clearance as indicated by increased urine output and decreased urine osmolality. The patient responded to conivaptan without any adverse effects.</description><identifier>ISSN: 0931-041X</identifier><identifier>EISSN: 1432-198X</identifier><identifier>DOI: 10.1007/s00467-008-0809-y</identifier><identifier>PMID: 18437428</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adolescent ; Benzazepines - administration & dosage ; Benzazepines - adverse effects ; Brief Report ; Fluid Therapy - methods ; Humans ; Hyponatremia - drug therapy ; Hyponatremia - etiology ; Inappropriate ADH Syndrome - drug therapy ; Inappropriate ADH Syndrome - etiology ; Lymphoma, Large B-Cell, Diffuse - complications ; Male ; Medicine & Public Health ; Nephrology ; Pediatrics ; Severity of Illness Index ; Tumor Lysis Syndrome - prevention & control ; Urology</subject><ispartof>Pediatric nephrology (Berlin, West), 2008-08, Vol.23 (8), p.1367-1370</ispartof><rights>IPNA 2008</rights><rights>COPYRIGHT 2008 Springer</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c533t-8602aa63a66b4579cd6b216801286ad3df93d695c64ae718aa70e2a2ca1c3c623</citedby><cites>FETCH-LOGICAL-c533t-8602aa63a66b4579cd6b216801286ad3df93d695c64ae718aa70e2a2ca1c3c623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00467-008-0809-y$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00467-008-0809-y$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18437428$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rianthavorn, Pornpimol</creatorcontrib><creatorcontrib>Cain, Joan P.</creatorcontrib><creatorcontrib>Turman, Martin A.</creatorcontrib><title>Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH</title><title>Pediatric nephrology (Berlin, West)</title><addtitle>Pediatr Nephrol</addtitle><addtitle>Pediatr Nephrol</addtitle><description>The available treatment options for hyponatremia secondary to SIADH are limited and not completely effective. Conivaptan is a vasopressin 1a and 2 receptor antagonist recently approved by the US Food and Drug Administration (FDA) for treating euvolemic and hypervolemic hyponatremia in adult patients. However, data on efficacy and safety of conivaptan in pediatrics are limited. We report a case of a 13-year-old boy with extensively metastasized anaplastic large-cell lymphoma. He also developed hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) prior to chemotherapy initiation. SIADH management in this case was complicated when fluid restriction was not safely attainable. Conivaptan played a significant role in this situation by allowing provision of a large amount of intravenous fluid prior to and during induction chemotherapy. It proved to be an important component in preventing uric acid nephropathy/tumor lysis syndrome. Conivaptan induced free-water clearance as indicated by increased urine output and decreased urine osmolality. The patient responded to conivaptan without any adverse effects.</description><subject>Adolescent</subject><subject>Benzazepines - administration & dosage</subject><subject>Benzazepines - adverse effects</subject><subject>Brief Report</subject><subject>Fluid Therapy - methods</subject><subject>Humans</subject><subject>Hyponatremia - drug therapy</subject><subject>Hyponatremia - etiology</subject><subject>Inappropriate ADH Syndrome - drug therapy</subject><subject>Inappropriate ADH Syndrome - etiology</subject><subject>Lymphoma, Large B-Cell, Diffuse - complications</subject><subject>Male</subject><subject>Medicine & Public Health</subject><subject>Nephrology</subject><subject>Pediatrics</subject><subject>Severity of Illness Index</subject><subject>Tumor Lysis Syndrome - prevention & control</subject><subject>Urology</subject><issn>0931-041X</issn><issn>1432-198X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kstu1DAUhiMEokPhAdggi0V3Kb4kjrMcFXqRKrGASt1FZ5yTjCvHDnYyVR6Bt8bDjFRARV5Y8vk-6_j4z7L3jJ4zSqtPkdJCVjmlKqeK1vnyIluxQvCc1er-ZbaitWA5Ldj9SfYmxgeawFLJ19kJU4WoCq5W2c-7iMR3RHtndjBO4MjkCVjrHwn0fcAYzQ7JdmkDTMb_ro4Bd-gmMs2DD8Qu0UQSF9cGPyAxjgAZsTUwBaPJmKw9-2imLbEQesw1WpusYdz6AQi4lny7WX--fpu96sBGfHfcT7O7yy_fL67z269XNxfr21yXQky5kpQDSAFSboqyqnUrN5xJRRlXElrRdrVoZV1qWQBWTAFUFDlwDUwLLbk4zc4O947B_5gxTs1g4r4ncOjn2HBKeVUzlsCP_4APfg4u9dZwzkXJ0iwTlB-gHiw2xnV-CqB7dBjAeoedScdrocqCSlVUiT9_hk-rxcHoZ4WzP4Qtgp220dt5_xnxb5AdQB18jAG7ZgxmgLA0jDb7uDSHuDQpBc0-Ls2SnA_HJ86bAdsn45iPBPADEFPJ9RieZvD_W38BSJ_LNA</recordid><startdate>20080801</startdate><enddate>20080801</enddate><creator>Rianthavorn, Pornpimol</creator><creator>Cain, Joan P.</creator><creator>Turman, Martin A.</creator><general>Springer Berlin Heidelberg</general><general>Springer</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>20080801</creationdate><title>Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH</title><author>Rianthavorn, Pornpimol ; Cain, Joan P. ; Turman, Martin A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c533t-8602aa63a66b4579cd6b216801286ad3df93d695c64ae718aa70e2a2ca1c3c623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Adolescent</topic><topic>Benzazepines - administration & dosage</topic><topic>Benzazepines - adverse effects</topic><topic>Brief Report</topic><topic>Fluid Therapy - methods</topic><topic>Humans</topic><topic>Hyponatremia - drug therapy</topic><topic>Hyponatremia - etiology</topic><topic>Inappropriate ADH Syndrome - drug therapy</topic><topic>Inappropriate ADH Syndrome - etiology</topic><topic>Lymphoma, Large B-Cell, Diffuse - complications</topic><topic>Male</topic><topic>Medicine & Public Health</topic><topic>Nephrology</topic><topic>Pediatrics</topic><topic>Severity of Illness Index</topic><topic>Tumor Lysis Syndrome - prevention & control</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rianthavorn, Pornpimol</creatorcontrib><creatorcontrib>Cain, Joan P.</creatorcontrib><creatorcontrib>Turman, Martin A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Pediatric nephrology (Berlin, West)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rianthavorn, Pornpimol</au><au>Cain, Joan P.</au><au>Turman, Martin A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH</atitle><jtitle>Pediatric nephrology (Berlin, West)</jtitle><stitle>Pediatr Nephrol</stitle><addtitle>Pediatr Nephrol</addtitle><date>2008-08-01</date><risdate>2008</risdate><volume>23</volume><issue>8</issue><spage>1367</spage><epage>1370</epage><pages>1367-1370</pages><issn>0931-041X</issn><eissn>1432-198X</eissn><abstract>The available treatment options for hyponatremia secondary to SIADH are limited and not completely effective. Conivaptan is a vasopressin 1a and 2 receptor antagonist recently approved by the US Food and Drug Administration (FDA) for treating euvolemic and hypervolemic hyponatremia in adult patients. However, data on efficacy and safety of conivaptan in pediatrics are limited. We report a case of a 13-year-old boy with extensively metastasized anaplastic large-cell lymphoma. He also developed hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) prior to chemotherapy initiation. SIADH management in this case was complicated when fluid restriction was not safely attainable. Conivaptan played a significant role in this situation by allowing provision of a large amount of intravenous fluid prior to and during induction chemotherapy. It proved to be an important component in preventing uric acid nephropathy/tumor lysis syndrome. Conivaptan induced free-water clearance as indicated by increased urine output and decreased urine osmolality. The patient responded to conivaptan without any adverse effects.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>18437428</pmid><doi>10.1007/s00467-008-0809-y</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0931-041X |
| ispartof | Pediatric nephrology (Berlin, West), 2008-08, Vol.23 (8), p.1367-1370 |
| issn | 0931-041X 1432-198X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_20027911 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Adolescent Benzazepines - administration & dosage Benzazepines - adverse effects Brief Report Fluid Therapy - methods Humans Hyponatremia - drug therapy Hyponatremia - etiology Inappropriate ADH Syndrome - drug therapy Inappropriate ADH Syndrome - etiology Lymphoma, Large B-Cell, Diffuse - complications Male Medicine & Public Health Nephrology Pediatrics Severity of Illness Index Tumor Lysis Syndrome - prevention & control Urology |
| title | Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T06%3A12%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20conivaptan%20to%20allow%20aggressive%20hydration%20to%20prevent%20tumor%20lysis%20syndrome%20in%20a%20pediatric%20patient%20with%20large-cell%20lymphoma%20and%20SIADH&rft.jtitle=Pediatric%20nephrology%20(Berlin,%20West)&rft.au=Rianthavorn,%20Pornpimol&rft.date=2008-08-01&rft.volume=23&rft.issue=8&rft.spage=1367&rft.epage=1370&rft.pages=1367-1370&rft.issn=0931-041X&rft.eissn=1432-198X&rft_id=info:doi/10.1007/s00467-008-0809-y&rft_dat=%3Cgale_proqu%3EA385406847%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222351586&rft_id=info:pmid/18437428&rft_galeid=A385406847&rfr_iscdi=true |